SCHEMBL30337668

SCHEMBL30337668

Fc1ccc(-c2cc3ccc(F)c(F)c3[nH]2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.43
GCGR P47871 5/20 0.41
MAPK14 Q16539 5/20 0.41
CCNB2 O95067 1/20 0.40
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40
CCNB3 Q8WWL7 1/20 0.40
MPL P40238 2/20 0.39
CTSV O60911 1/20 0.38
CTSL P07711 1/20 0.38
NPY5R Q15761 1/20 0.38
MAPT P10636 1/20 0.38
KIT P10721 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22118352 1.00 CYP1A1 (0.43) CYP1A1GCGRMAPK14CCNB2CDK1
SCHEMBL22118349 0.78 CYP1A1 (0.45) CYP1A1GCGRMAPK14CCNB2CDK1
SCHEMBL24098707 0.76 GCGR (0.41) CYP1A1GCGRMAPK14CCNB2CDK1
SCHEMBL30218307 0.76 GCGR (0.41) CYP1A1GCGRMAPK14CCNB2CDK1
SCHEMBL24098975 0.76 KIT (0.47) CYP1A1GCGRMAPK14CCNB2CDK1
SCHEMBL24098965 0.72 NPY5R (0.42) CYP1A1GCGRMAPK14CCNB2CDK1
SCHEMBL694774 0.72 MGAM (0.45) CYP1A1GCGRMAPK14CTSVCTSL
SCHEMBL24098674 0.72 MAPT (0.40) CYP1A1GCGRMAPK14CCNB2CDK1
SCHEMBL694712 0.72 CCNB2 (0.38) CYP1A1GCGRMAPK14CCNB2CDK1
SCHEMBL695284 0.70 ALDH1A1 (0.57) CYP1A1GCGRMAPK14CTSVCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042878-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2025-02-06 US disclosed
US-12060346-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-08-13 US disclosed
CN-113453760-B APOL1 inhibitors and methods of use thereof 弗特克斯药品有限公司 2024-05-24 CN disclosed
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-08-31 US disclosed
US-11618746-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, SAAL1 CYP1A1 4701/4885GCGR 1169/4885MAPK14 3772/4885
US-12060346-B2 Inhibitors of APOL1 and methods of using same APOL1, APOB, SAAL1 CYP1A1 4701/4885GCGR 1169/4885MAPK14 3772/4885
US-20250042878-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, SAAL1 CYP1A1 4701/4885GCGR 1169/4885MAPK14 3772/4885
US-11618746-B2 Inhibitors of APOL1 and methods of using same APOL1, APOB, NPC1L1 CYP1A1 4371/4885GCGR 970/4885MAPK14 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.